RxDoctor Payments Data

John Nepomuceno, MD

Family Medicine · Redding, CANPI 1477673770

Payments from drug & device makers

$981in general payments, 2019–2025

Across 17 payments — averaging $57.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$341
  • GSK$189
  • Abbott$147
  • Organogenesis Inc.$94
  • Philips North America LLC$73
  • AbbVie$64
  • plus $72 from 2 others

What the payments were for

  • Food & beverage$981100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$981 in reported general payments places this provider in the 70th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$246,511
Medicare patients
767
Services billed
2,068

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban189$117,219
XareltoRivaroxaban185$79,297
JardianceEmpagliflozin84$40,075
MyrbetriqMirabegron57$27,548
JanuviaSitagliptin Phosphate42$23,864
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$20,538
FarxigaDapagliflozin Propanediol18$9,321
Quetiapine Fumarate424$7,688
EntrestoSacubitril/Valsartan15$7,299
Levothyroxine Sodium535$7,076
LinzessLinaclotide12$6,773
Tresiba Flextouch U-200Insulin Degludec12$6,746
Divalproex Sodium179$5,998
Atorvastatin Calcium390$5,842
ZenpepLipase/Protease/Amylase13$5,102

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$189$25,63543 claims
MerckJanuvia$16$23,86442 claims
NovartisEntresto$56$7,29915 claims
AbbVieLinzess$64$6,77312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 10,533 family medicine providers in California.

Other family medicine in Redding

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →